Vertaling van "about the product " (Nederlands → Frans) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

As regards D- glucuronolactone, the SCF confirms its reservations about a daily chronic intake of 840 mg of the product (1.4 can) and an acute intake of 1 800 mg of the product (3 cans) via this type of drink, taking into account that the natural intake of D-glucuronolactone via food amounts to 1 to 2 mg/day (SCF, 2003).
Pour le D-glucuronolactone, le SCF confirme ses réserves dans le cadre d’un apport journalier chronique de 840 mg de produit (1,4 canette) et d’un apport aigu de 1.800 mg de produit (3 cannettes) via ce type de boisson et ce, tenant compte du fait que l’apport alimentaire naturel en D-glucuronolactone est de 1 à 2 mg/jour (SCF, 2003).

Improvement of knowledge about the method of application of biocidal products PT8, 14 and 18 (CRA) 2008 (enkel in het Engels)
Improvement of knowledge about the method of application of biocidal products PT8, 14 and 18 (CRA) 2008 (en anglais uniquement)

About Humana Humana Inc., headquartered in Louisville, Kentucky, is a leading healthcare company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being.
Humana Inc., headquartered in Louisville, Kentucky, is a leading healthcare company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being.

The Ministry of Public Health has, however, requested that a post-consumption follow-up be carried out and that the general public be given detailed information about the product’s adverse effects.
Le Ministère de la Santé a cependant demandé que soit mis en œuvre un suivi post-consommation et une information précise à l’attention du grand public sur les effets indésirables de ce produit.

Various roadshows were organised in order to inform the FAMHP stakeholders about this new activity within the FAMHP and to provide a coherent explanation of recent regulations regarding medicines for veterinary use and the distribution of these products in particular; the roadshows were organised for and in collaboration with the veterinarian professional organisations.
Various roadshows were organised in order to inform the FAMHP stakeholders about this new activity within the FAMHP and to provide a coherent explanation of recent regulations regarding medicines for veterinary use and the distribution of these products in particular; the roadshows were organised for and in collaboration with the veterinarian professional organisations.

Information about medicines and health products e-mail info.FAGG_AFMPS@fagg-afmps.be
Information about medicines and health products e-mail info.FAGG_AFMPS@fagg-afmps.be

The official role of this commission is to issue advice to determine the status of products when there is any doubt or uncertainty about whether or not they are medicines.
The official role of this commission is to issue advice to determine the status of products when there is any doubt or uncertainty about whether or not they are medicines.

The latter involves, on the one hand, the provision of relevant information about authorised medicines and health products aimed at the different target groups, and, on the other hand, the partnership with bodies responsible for the distribution of independent information, such as the BCFI - CBIP.
The latter involves, on the one hand, the provision of relevant information about authorised medicines and health products aimed at the different target groups, and, on the other hand, the partnership with bodies responsible for the distribution of independent information, such as the BCFI - CBIP.

In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.
In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.